Healthtech startup Plazza, which develops a technological platform for retail drug sales and fast medication delivery, has successfully closed a $15 million funding round in Series A. This round was co-led by Accel, Elevation Capital, and Nexus Venture Partners, with participation from existing investors All In Capital and Better Capital.
Plans for the New Capital
The Bengaluru-based company stated that the funds raised will be used to strengthen its technological infrastructure, improve its AI-based intelligent inventory management system, expand operational capabilities, and increase the reach of its pharmacy network into new regions.
Solving India's Healthcare Problem
Plazza was founded in 2024 by Aman Priyadarshi with the goal of addressing one of India's most pressing healthcare issues—ensuring patients have access to prescription drugs when needed. The Indian pharmaceutical retail market is valued at over $30 billion, but it is largely controlled by independent local pharmacies, which typically stock only about 5,000 items out of more than 100,000 available products. This forces patients to visit multiple pharmacies to fulfill a complete prescription.
Innovative Operating Model
Plazza's model combines local pharmacies with AI-driven inventory planning, which predicts local demand and determines exactly which medications each point of sale should stock. The company claims that each location carries over 40,000 Stock Keeping Units (SKUs), enabling a prescription fulfillment rate exceeding 95%, significantly surpassing the industry average of 50–60%. Furthermore, it is reported that medication delivery takes place within 15–30 minutes.
Founder's Vision
Founder and CEO Priyadarshi emphasized that access to medicine should not depend on luck. He objected to situations where patients must visit several pharmacies or wait days due to fragmented inventory, insisting that drug retail must be rebuilt around technology, not just shelves.
Development Strategy and Valuation
According to Priyadarshi, the new funding will allow Plazza to enhance the analytical capabilities of each location, expand its presence across more districts, and create a reliable customer experience with the pharmacy. The startup's AI system continuously analyzes drug prescription patterns at the district level, ensuring each location has a tailored inventory. Chirag Chadha, a partner at Elevation Capital, noted that Plazza attracted attention not only for its delivery speed but also for its fundamentally different operational approach, built on AI-powered inventory management and district-level demand.
Financial Metrics and Investments
Since its launch, the company reports an almost 27-fold growth in its Gross Merchandise Value (GMV) between June 2025 and March 2026. According to Plazza data, repeat customers now place orders with an average basket size approximately 30% larger than first-time buyers. This round follows a seed funding round of $1.4 million announced in September 2025. Despite the cautious investment climate, the healthtech sector remains one of the most resilient segments of venture capital funding in India, as investors continue to support startups focused on improving accessibility, operational efficiency, and reducing the cost of medical care.
Competitive Advantage
Investors in the latest round believe that Plazza's competitive advantage lies in solving a structural problem, rather than simply offering faster delivery. Pratik Agarwal, a partner at Accel, noted that Plazza transforms this experience by combining deep drug stock in pharmacies, reliable local execution, 24/7 access, and a consumer-grade technology level.